Search Results - "Lezama, M. Sotelo"

Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small cell lung cancer (NSCLC) patients by Mielgo Rubio, X., Sereno Moyano, M., Chara, L.E., López-Castro, R., Rubio-Martínez, J., Velastegui, A., Olier-Garate, C., Falagán, S., Gómez-Barreda, I., Riquelme, A., Silva-Ruiz, J., Moreno-Rubio, J., López, C., Bueno, C., Cardeña, A., Pérez-Fernández, E., Martí-Castelló, M.P., Sotelo-Lezama, M.J.

Get full text

Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC) by Gajate Borau, P., Martin Marino, A., Gallegos Sancho, I., Villa Guzman, J.C., Velastegui, A., Alonso Gordoa, T., Castellano, D., Rubio Romero, G., Pinto Marin, A., Villalobos Leon, L., Maximiano Alonso, C., Sotelo-Lezama, M.J., Sereno Moyano, M., Rodríguez, J.F., Perezagua Marin, C., Ballesteros, J., Marrupe Gonzalez, D., Rodriguez Lajusticia, L., Tafalla García, J.J., Aguado, C.

Get full text

1509PApplicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small cell lung cancer (NSCLC) by Mielgo Rubio, X, Gomez Rueda, A, Antoñanzas, M, Falagan, S, Núñez, J A, Sánchez Peña, A M, Gómez-Barreda, I, Martinez Moreno, E, Cerezo Gonzalez, S, Cabezón Gutiérrez, L, Sanchez Torres, J M, Jimenez Munarriz, B E, Cervera, R, Pangua Mendez, C, Calles Blanco, A, Lopez Martin, A, López Castro, R, Sotelo Lezama, M J, Pérez Fernández, E, Cruz, P

“…Abstract Background Derived neutrophils/(leukocytes-neutrophils) ratio (dNLR) and lactate dehydrogenase (LDH) level have been correlated with immune checkpoint…”
Get full text

1413PNeutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small cell lung cancer (NSCLC) patients by Mielgo Rubio, X, Sereno Moyano, M, Chara, L E, López-Castro, R, Rubio-Martínez, J, Velastegui, A, Olier-Garate, C, Falagán, S, Gómez-Barreda, I, Riquelme, A, Silva-Ruiz, J, Moreno-Rubio, J, López, C, Bueno, C, Cardeña, A, Pérez-Fernández, E, Martí-Castelló, M P, Sotelo-Lezama, M J

Get full text

823PEfficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC) by Gajate Borau, P, Martin Marino, A, Gallegos Sancho, I, Villa Guzman, J C, Velastegui, A, Alonso Gordoa, T, Castellano, D, Rubio Romero, G, Pinto Marin, A, Villalobos Leon, L, Maximiano Alonso, C, Sotelo-Lezama, M J, Sereno Moyano, M, Rodríguez, J F, Perezagua Marin, C, Ballesteros, J, Marrupe Gonzalez, D, Rodriguez Lajusticia, L, Tafalla García, J J, Aguado, C

Get full text

1007PCETUXIMAB AND CONCURRENT RADIATION (CTX-RT) FOR SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN ELDERLY AND MULTI-MORBID PATIENTS by Carhuapoma, H.R. Callata, Aguado, C., Vazquez, G., Camarero, S. Cabezas, Lezama, M. Sotelo, Moreno, M.C. Iglesias, Manzano, A., Acosta, D., Díaz-Rubio, E., Segura, P. Perez

“…Abstract Aim: Treatment with CTX-RT in patients (pts) with locally advanced or recurrent SCCHN has shown benefits in overall survival (OS) and locoregional…”
Get full text

Cetuximab and Concurrent Radiation (Ctx-Rt) for Squamous Cell Carcinoma of the Head and Neck (Scchn) in Elderly and Multi-Morbid Patients by Carhuapoma, H.R. Callata, Aguado, C., Vazquez, G., Camarero, S. Cabezas, Lezama, M. Sotelo, Moreno, M.C. Iglesias, Manzano, A., Acosta, D., Díaz-Rubio, E., Segura, P. Perez

Get full text

362PASSESSMENT OF TREATMENT RESPONSE WITH FULVESTRANT (F) 500 MG IN STANDARD CLINICAL PRACTICE THROUGH A RETROSPECTIVE STUDY: NCT01509625 by Blancas, I., Fontanillas, M., Conde Herrero, V., Lao, J., Martinez de Dueñas, E., Sotelo Lezama, M., JaÉn-Morago, A., Bayo, J.L., Carabantes, F., Illaramendi, J.J., Gordón, M., Ruiz-Borrego, M., Cruz, J., García-Palomo, A., Mendiola, C., Perez-Ruiz, E., Cañada, J.M. Baena, Martínez, N., Esquerdo, G., Bofill, J. Salvador

“…Abstract Aim: After CONFIRM study results, fulvestrant 500 mg (F500) became one of the standard treatments for patients with oestrogen receptor (ER+)…”
Get full text

Assessment of Treatment Response with Fulvestrant (F) 500 Mg in Standard Clinical Practice Through a Retrospective Study: Nct01509625 by Blancas, I., Fontanillas, M., Conde Herrero, V., Lao, J., Martinez de Dueñas, E., Sotelo Lezama, M., JaÉn-Morago, A., Bayo, J.L., Carabantes, F., Illaramendi, J.J., Gordón, M., Ruiz-Borrego, M., Cruz, J., García-Palomo, A., Mendiola, C., Perez-Ruiz, E., Cañada, J.M. Baena, Martínez, N., Esquerdo, G., Bofill, J. Salvador

Get full text

567PROLE OF CIRCULATING TUMOR CELLS (CTC) IN STAGE III COLORECTAL CANCER (CRC) by Lezama, M. Sotelo, Sastre, J., Veganzones, S., Orden, V. De La, Viéitez, J.M., Alonso, V., Grávalos, C., Escudero, P., Vera, R., Aranda, E., Alfonso, P. García, Plazas, J. Gallego, López, C., Pericay, C., Arrivi, A., Lazcano, M.P. Vicente, Ballesteros, P., Elez, E., López-Ladrón, A., Díaz-Rubio, E.

“…Abstract Aim: CTC detection has proved to be an independent prognostic factor in metastatic CRC. However, the prognostic role of CTC in early CRC has not been…”
Get full text

Role of Circulating Tumor Cells (Ctc) in Stage III Colorectal Cancer (Crc) by Lezama, M. Sotelo, Sastre, J., Veganzones, S., De Orden, V.La, Viéitez, J.M., Alonso, V., Grávalos, C., Escudero, P., Vera, R., Aranda, E., Alfonso, P. García, Plazas, J. Gallego, López, C., Pericay, C., Arrivi, A., Lazcano, M.P. Vicente, Ballesteros, P., Elez, E., López-Ladrón, A., Díaz-Rubio, E.

Get full text